Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics
Authors:
- 14 November 2022
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 352, 861-878
Abstract
No abstract availableKeywords
Funding Information
- NRF
- Ministry of Science, ICT and Future Planning (2021R1A2C3009556, 2022R1A5A2018865)
- National Research Foundation of Korea
This publication has 190 references indexed in Scilit:
- Non-coding RNAs in human diseaseNature Reviews Genetics, 2011
- Novel adeno-associated viral vectors for retinal gene therapyGene Therapy, 2011
- Targeting RNA to treat neuromuscular diseaseNature Reviews Drug Discovery, 2011
- Silencing of microRNA families by seed-targeting tiny LNAsNature Genetics, 2011
- Targeted Delivery of Antisense Oligodeoxynucleotide by Transferrin Conjugated pH-Sensitive Lipopolyplex Nanoparticles: A Novel Oligonucleotide-Based Therapeutic Strategy in Acute Myeloid LeukemiaMolecular Pharmaceutics, 2009
- Efficient Delivery of Antisense Oligodeoxyribonucleotide G3139 by Human Serum Albumin-Coated LiposomesMolecular Pharmaceutics, 2009
- Antitumor activity of a novel antisense oligonucleotide against Akt1Journal of Cellular Biochemistry, 2009
- Cationic liposomal lipids: From gene carriers to cell signalingProgress in Lipid Research, 2008
- In vivo and in vitro effects of a HIF‐1α inhibitor, RX‐0047Journal of Cellular Biochemistry, 2008
- Preparation and evaluation of cholesteryl PAMAM dendrimers as nano delivery agents for antisense oligonucleotidesColloids and Surfaces A: Physicochemical and Engineering Aspects, 2008